Zydus Lifesciences Inks a Deal with CVS Caremark

Zydus Lifesciences Ltd. is a global leader in the life sciences sector, renowned for its innovative approach to discovering, developing, manufacturing, and marketing an extensive array of healthcare solutions.

Strategic Agreement with CVS Caremark

On January 7, 2025, Zydus Lifesciences Ltd. experienced a notable surge in buying activity, following the announcement of a strategic agreement with CVS Caremark. This partnership will see Zydus’ Zituvio and its combination products added to the CVS Caremark template formulary, effective from January 1, 2025.

The official statement revealed, “Zydus Lifesciences Ltd., a forward-thinking, innovation-driven global healthcare company, is delighted to announce its collaboration with CVS Caremark, a subsidiary of CVS Health (NYSE: CVS), to include Zituvio, Zituvimet, and Zituvimet XR (Sitagliptin | Sitagliptin and Metformin Hydrochloride) tablets in its template formulary.”

About Zituvio

Zituvio and its associated products feature the active ingredients sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide. These are prescribed as adjuncts to diet and exercise to help improve glycemic control in adults suffering from type 2 diabetes mellitus.

Share Price Performance

Zydus Lifesciences Ltd shares were trading at ₹980.00 on the NSE in intraday trading on January 8, 2025. Over the past year, Zydus Lifesciences shares have surged by an impressive 34.6%, significantly outperforming the Sensex, which rose by just 8.2%.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.